The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study

Inclusion Criteria:

* A histological diagnosis of adenocarcinoma of the prostate
* Life expectancy greater than 5 years.
* ECOG performance status \< 1.
* Signed, written informed consent prior to randomization.
* Any one, or more, of the following criteria:

  * TNM stage T2c, T3a or T3b
  * Gleason score 8 to 10, as determined by central institutional review.
  * PSA \> 20 mcg/L, but \< 50 mcg/L. OR Have a \> 50% chance of recurrence after radical prostatectomy, as predicted by the Kattan Nomogram and
  * Post - op PSA \< 1.0 mcg/L.
  * Must be able to start protocol treatment within 6 months from date of surgery.
* No evidence of metastasis, as determined by bone scan and Chest x-ray/CT abdomen/pelvis.
* Adequate marrow reserve and end - organ function

  * Leukocytes \> 3,000/mcL.
  * Absolute neutrophil count \> 1,500/mcL
  * Platelets \> 100,000/mcL
  * Total bilirubin \< 1.2 x upper limit of normal for the institution.
  * AST(SGOT)/ALT(SGPT) greater than 1.5 X institutional upper limit of normal
  * Creatinine within normal institutional limits OR
  * Creatinine clearance \> 60 mL/min using the Crockfort - Gault formula for patients with creatinine levels above institutional normal.

Exclusion Criteria:

* PSA \> 50 µg/L.
* Previous pelvic radiotherapy
* Sensitivity to Docetaxel chemotherapy.
* Grade 2 or greater NCI CTCAE version 3.0 neuropathy.
* Prior malignancy within the last 5 years, other than prostate cancer, except:

  * Patients with adequately treated non - melanoma cutaneous malignancies.
  * Patients with a history of a curatively treated malignancy (including patients with superficial bladder cancer) who have not had evidence of recurrence for a minimum of 5 years.
* Patients with a history of hypersensitivity to polysorbate 80.
* Patients with a known history of viral hepatitis (B,C).